Virpax Pharma declines after Nasdaq non-compliance notice

Virpax Pharmaceuticals

25/11/2024 10:53

** Shares of Virpax Pharmaceuticals  VRPX.O  fall 10.4% to
50 cents premarket
        ** Late on Friday, co disclosed it had received notice
on Nov. 19 from Nasdaq about non-compliance with independent
director and audit committee rules
    ** Co says it has appointed Esha Randhawa as an independent
director and audit committee member; adds that it has regained
compliance with listing rule
    ** Plans to notify Nasdaq of its compliance - VRPX 
    ** As of last close, stock had fallen 82.3% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))